Intervention for End Stage Renal Disease (ESRD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Pennsylvania, Philadelphia, PA
End Stage Renal Disease (ESRD)+2 More
Nudge for PHPC Referral - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Home palliative care needs are often under-recognized in patients with End-Stage Renal Disease (ESRD). This pilot study is designed to evaluate the feasibility and acceptability of an initiative to enhance referrals to Penn Home Palliative Care compared with usual care among hemodialysis-dependent ESRD patients admitted to a Penn hospital. Results will inform a future pragmatic trial comparing the effectiveness of home palliative care compared with usual care among ESRD patients. Evaluating the effectiveness of home palliative care services is critical to determine whether increasing access to these services would improve patient-centered outcomes for these high-need patients.

Eligible Conditions

  • End Stage Renal Disease (ESRD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for End Stage Renal Disease (ESRD)

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: Baseline - 180 days

Baseline - 180 days
Acceptability of home palliative care referral among clinician stakeholders
Follow-up Home Palliative Care Visits
Hospital-free days
Mortality
Baseline - 45 days
Rate of Home Palliative Care Receipt
Receipt of Home Palliative Care

Trial Safety

Safety Progress

1 of 3

Other trials for End Stage Renal Disease (ESRD)

Trial Design

2 Treatment Groups

Usual Care
1 of 2
Intervention
1 of 2
Active Control
Experimental Treatment

114 Total Participants · 2 Treatment Groups

Primary Treatment: Intervention · No Placebo Group · N/A

Intervention
Behavioral
Experimental Group · 1 Intervention: Nudge for PHPC Referral · Intervention Types: Behavioral
Usual CareNoIntervention Group · 1 Intervention: Usual Care · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline - 180 days

Trial Background

Prof. Scott Halpern, Professor of Medicine
Principal Investigator
University of Pennsylvania
Closest Location: University of Pennsylvania · Philadelphia, PA
Photo of Hospital of the University of Pennsylvania  1Photo of Hospital of the University of Pennsylvania  2Photo of University of Pennsylvania  3
2011First Recorded Clinical Trial
4 TrialsResearching End Stage Renal Disease (ESRD)
1048 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are an adult (18 years of age or older) hospitalized at one of the three study hospitals.
Patient resides in the five-county area surrounding Philadelphia which is served by the Penn Home Palliative Care services.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.